IRVINE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care ...
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, has received CE Mark for its HemoSphere advanced ...
Edwards Lifesciences Corp.'s buy of Cas Medical Systems Inc. (Casmed) this spring appears to have borne fruit. The Irvine, Calif.-based company reported that the U.S. FDA has granted clearance for a ...
Edwards Lifesciences Corporation EW has been gaining from huge potential in the Structural Heart business. The company ended the first quarter of 2022 with better-than-expected results. Strong sales ...
The “SMART TRENDS Study,” officially titled “Acumen HPI Smart Alerts and Smart Trends to Improve Compliance With an Intra-operative Hemodynamic Management Algorithm and Reduce Renal Injury Following ...
On Dec 26, we issued an updated research report on Edwards Lifesciences Corporation EW. The hugely untapped potential in the emerging markets aids the company. However, reimbursement issue deters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results